EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database

Masami Tsuchiya iD, Tomofumi Ishikawa iD, Takamasa Sakai iD, Satoko Hori iD, Taku Obara iD

Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)

DOI: 10.1002/pds.70508 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 16.10.2026. Verfasst von Masami Tsuchiya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan. Hauptthemen laut MEDLINE: Pregnancy Complications, Neoplastic, Pregnancy Outcome, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To characterize cancer treatment during pregnancy and maternal and infant outcomes among women with cancer identified during pregnancy in Japan.

Methods

In this descriptive cohort study, we used mother‐infant linkage data from the JMDC claims database from 2005 to 2024. Live‐birth pregnancies were considered eligible when a malignant neoplasm (ICD‐10 C00–C97) was recorded between the estimated pregnancy onset and delivery. Exposure was defined as at least one anticancer agent prescribed between the diagnosis and delivery; surgery and radiation therapy were also identified. The outcomes were preterm delivery and major congenital malformation at 6 months of age. Pregnancies without a diagnosis of malignant neoplasms constituted the internal reference group.

Results

Of the 500 pregnancies with cancer identified during pregnancy, 16 (3.2%) had an anticancer agent prescribed, 46 (9.2%) underwent surgery for malignant tumors, and none underwent radiation therapy. Cancer was identified in the second trimester in 10 of the 16 pregnancies with exposure (62.5%) and in 128 of the 484 pregnancies without exposure (26.4%). All eight pregnancies with breast cancer received an anthracycline with cyclophosphamide. The frequencies in the reference group ( n = 236 002), without exposure, and with exposure were 12.0%, 20.9%, and 37.5% for preterm delivery and 6.1%, 9.1%, and 12.5% for major congenital malformation, respectively.

Conclusions

Cancer identified during pregnancy was treated in a minority of women, and anticancer agents were most often prescribed when cancer was identified in the second trimester. Outcomes were recorded more often in pregnancies with cancer but cannot be attributed to anticancer agent exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pregnancy Complications, NeoplasticPregnancy OutcomeAntineoplastic AgentsNeoplasmsHumansFemalePregnancyJapanDatabases, FactualCohort StudiesAdultInfant, NewbornPremature BirthInfantYoung AdultEast Asian People

Stichwörter der Autor:innen

administrative dataantineoplastic agentscancer during pregnancyclaimscongenital abnormalitiespharmacoepidemiologypregnancy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
  • Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Division of Preventive Medicine and Epidemiology, Tohoku University Tohoku Medical Megabank Organization, Sendai, Miyagi, Japan.
  • Department of Clinical Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.

ORCID-Profile: Masami Tsuchiya, Tomofumi Ishikawa, Takamasa Sakai, Satoko Hori, Taku Obara

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tsuchiya, M., Ishikawa, T., Sakai, T., Hori, S., & Obara, T. (2026). Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70508

Vancouver

Tsuchiya M, Ishikawa T, Sakai T, Hori S, Obara T. Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70508

BibTeX
@article{Tsuchiya2026,
  author = {Tsuchiya, Masami and Ishikawa, Tomofumi and Sakai, Takamasa and Hori, Satoko and Obara, Taku},
  title = {Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {11},
  doi = {10.1002/pds.70508}
}
Kostenlos starten →